Scientists achieve landmark breakthrough in gene-editing therapy inside living body

Scientists have completed the first clinical application of prime editing, a revolutionary gene-editing technique that modifies DNA sequences within a living human body without making permanent breaks in the genetic code. The breakthrough represents a major advance over earlier CRISPR-based gene-editing approaches and demonstrates the practical feasibility of in vivo genetic intervention.

Prime editing works by using a modified enzyme to search for specific DNA sequences and rewrite them with greater precision than previous methods. Unlike traditional gene-editing approaches that can cause double-strand breaks in DNA, prime editing creates temporary, single-strand breaks that are naturally repaired by cellular mechanisms, reducing the risk of unintended genetic changes.

The successful demonstration in a human patient signals that prime editing could eventually treat a wide range of genetic disorders, from inherited blindness to blood diseases and metabolic conditions. Researchers emphasize that while this represents a proof-of-concept, further clinical trials are necessary to establish safety profiles and efficacy across different patient populations.

Genetic medicine specialists in South Asia note the potential implications for regional healthcare systems, particularly given the prevalence of inherited genetic conditions in communities with higher rates of consanguinity. Medical experts anticipate that such therapies could eventually become accessible in the region as the technology matures and costs decrease.